Average Co-Inventor Count = 5.93
ph-index = 7
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Signal Pharmaceuticals, Inc. (21 from 169 patents)
2. Celgene Corporation (5 from 550 patents)
26 patents:
1. 12404241 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
2. 11873283 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
3. 11590139 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
4. 11331380 - Cereblon-based heterodimerizable chimeric antigen receptors
5. 11325889 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
6. 11166950 - Treatment of cancer with TOR kinase inhibitors
7. 11149007 - Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
8. 10940152 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
9. 10646493 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
10. 10576085 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
11. 10004735 - Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
12. 9980963 - Treatment of cancer with dihydropyrazino-pyrazines
13. 9937170 - Treatment of cancer with TOR kinase inhibitors
14. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
15. 9737535 - Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines